ImmunityBio Founder Reaffirms Grip as Stock Suffers Worst Selloff Since 2024 After Massive Rally
ImmunityBio, a biotechnology company known for its innovative cancer and immunotherapy research, has experienced its worst stock selloff since 2024, following a massive rally earlier this year. Despite the sharp decline, the company’s founder has reaffirmed his grip on the firm, signaling confidence in its long-term vision and pipeline. Background of ImmunityBio’s Rally ImmunityBio’s stock…